Planning and prioritizing direct-acting antivirals treatment for HCV patients in countries with limited resources: Lessons from the Egyptian experience

Elsharkawy, Aisha; Raziky, Maissa El; El-Akel, Wafaa; Elsaeed, Kadry; Eletreby, Rasha; Hassany, Mohamed; El-Sayed, Manal Hamdy; Kabil, Khaled; Ismail, Sohier Ahmed; El‐Serafy, Magdy; Abdelaziz, Ashraf Omar; Shaker, Mohamed; Yosry, Ayman; Doss, Wahid; Elshazly, Yehia; Esmat, Gamal; Waked, Imam

doi:10.1016/j.jhep.2017.11.034

Cited by 59 publications

(48 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…ALT was entirely improved in some patients' samples and these patients classified as responders, but other samples were in abnormal ranges, and therefore are considered as non-responding, and these results are in consistency with Deterding et al (2015). AST decreased significantly at week 4 of treatment with target combination used in this study and returned to normal range in responder, but in abnormal values in other patient samples and they considered as non-responders and this trend of results are in complete accordance with the study published by Elsharkawy et al (2018). This improvement in the liver enzymes was maintained until 12 weeks after the treatment.…”

Section: Figure 22 Linear Pearson Correlation Between Plt Response supporting

confidence: 89%

A Predictive and Comparative Study via Viral and Biochemical Measurements for Responders and Non-Responders Egyptian Hepatitis C Patients to Daclatasvir Plus Sofosbuvir Therapy

El-Gebaly

2018

Al-Azhar Journal of Pharmaceutical Sciences

View full text Add to dashboard Cite

Most of the liver diseases and hepatocellular carcinoma (HCC) worldwide is due to infection with hepatitis C virus. The developed new drugs in the last few years are promising, but patients response to such drugs are different. Therefore, to identify early the non-responding patients to SOF/DCV therapy for saving of medical costs and to guide them for appropriate treatment without wasting time, HCV RNA in conjunction with biochemical tests were measured during treatment (at week 4) for 100 blood samples from patients were positive for antibodies to (HCV), elevated liver enzymes (mean baseline serum ALT (±SD 123±2.7 U/L), RT-PCR baseline 355,000 IU/ ml. All patients were negative for hepatitis B virus. These patients were under treatment with DAC 60 mg/day plus Sofosbuvir 400 mg/day to give a predictive outcome of the extent of response or not to this therapy. In addition, the same analyses were performed after the end of course therapy (12 weeks) in order to compare the results of the predictive value. The obtained results at week 4 of treatment indicated that 95% of patients had been shifted to normal range for biochemical analysis measured in addition, viral load was decreased in 95% of patients, while at the end of treatment course (week 12) biochemical response was completely achieved in 98% of patients in a complete normalization ranges as well as, viral titer reached to the below detection limit. On the other hand, the rest of the patient samples still abnormal and classified as nonresponding.

show abstract

Section: Figure 22 Linear Pearson Correlation Between Plt Response supporting

confidence: 89%

A Predictive and Comparative Study via Viral and Biochemical Measurements for Responders and Non-Responders Egyptian Hepatitis C Patients to Daclatasvir Plus Sofosbuvir Therapy

El-Gebaly

2018

Al-Azhar Journal of Pharmaceutical Sciences

View full text Add to dashboard Cite

show abstract

“…These included phone calls to identify the cause of “no show,” issuing “certificates of cure,” and initiating hepatitis B vaccination free of charge. Those interventions increased SVR data capture significantly, although it still remained far from ideal …”

Section: The World’s Largest National Treatment Programmentioning

confidence: 99%

Hepatitis C Virus in Egypt: Interim Report From the World’s Largest National Program

Abdel-Razek

Hassany

El-Sayed

et al. 2019

Clinical Liver Disease

Self Cite

View full text Add to dashboard Cite

show abstract

“…While this level of treatment uptake exceeded the estimated 12% of patients per year required to reach the elimination targets (4725 treatments among the estimated 40 000 infected people who inject drugs), early uptake reflected the availability of large numbers of patients waiting for DAAs to become accessible and easy‐to‐reach patients commencing DAA therapy. It is unclear whether high treatment rates can be sustained, and in some other countries they have declined . The level of reduction that would put achievement of the elimination targets in Australia at risk is unclear.…”

mentioning

confidence: 99%

Australia needs to increase testing to achieve hepatitis C elimination

Scott

Sacks‐Davis

Wade

et al. 2020

Medical Journal of Australia

View full text Add to dashboard Cite

In 2015, the first World Health Organization viral hepatitis strategy 1 set specific targets for the global elimination of hepatitis C as a public health threat by 2030: that the incidence of hepatitis C virus infections be reduced by 80% and hepatitis C-related mortality by 65%. A major strategy for achieving these targets is to increase access to highly effective direct-acting antiviral (DAA) treatments. The WHO viral hepatitis strategy includes two further targets for 2030: that 90% of cases of hepatitis C are diagnosed and that 80% of people with chronic hepatitis C are treated. 1

show abstract

Planning and prioritizing direct-acting antivirals treatment for HCV patients in countries with limited resources: Lessons from the Egyptian experience

Cited by 59 publications

References 28 publications

A Predictive and Comparative Study via Viral and Biochemical Measurements for Responders and Non-Responders Egyptian Hepatitis C Patients to Daclatasvir Plus Sofosbuvir Therapy

A Predictive and Comparative Study via Viral and Biochemical Measurements for Responders and Non-Responders Egyptian Hepatitis C Patients to Daclatasvir Plus Sofosbuvir Therapy

Hepatitis C Virus in Egypt: Interim Report From the World’s Largest National Program

Australia needs to increase testing to achieve hepatitis C elimination

Contact Info

Product

Resources

About